In this webcast, panelists will discuss life sciences transfer pricing controversy trends and developments in select markets from Asia-Pacific and Europe, including the UK, Germany, France and Australia.
The latest EY report How to navigate global transfer pricing controversy in life sciences explores the growing tax authority scrutiny that life sciences companies are facing with regard to their transfer pricing practices. The unique attributes of the life sciences industry, coupled with an increasingly unpredictable legal and tax regulatory environment, and significant fiscal pressures faced by governments worldwide, have focused tax authorities’ attention on the industry and placed life sciences companies in the cross hairs.
Please join us in this webcast during which we will explore life sciences transfer pricing controversy trends and developments in select markets from Asia-Pacific and Europe, including the UK, Germany, France and Australia. Our team of life sciences and transfer pricing specialists will discuss and share their perspectives on emerging trends and hot topics relevant to these markets, including:
- Global transfer pricing controversy issues and trends developing across the sector
- Evolving controversy trends, audit approaches and things to look out for in key markets of Asia-Pacific and Europe
- Practical actions and key takeaways for life sciences multinationals to prepare for increasing and intensifying transfer pricing controversy
Panelists:
- Anna Lucey, Director, Tax, Ernst & Young LLP
- Jason Vella, EY International Tax and Transaction Services Partner, Transfer Pricing, Ernst & Young
- Joel Cooper, EY Global International Tax and Transactions Services Controversy Leader
- Oliver Wehnert, EY Europe West Tax Market Segment Leader, Health Science & Wellness, Ernst & Young GmbH
- Patrice Jan, Tax Partner & Co-leader of French Transfer Pricing Practice for EY Société d'Avocats
To go to the US-focused session, click here.
